{"id":866,"date":"2025-01-23T13:12:16","date_gmt":"2025-01-23T13:12:16","guid":{"rendered":"https:\/\/www.nordicbioscience.com\/?post_type=biomarker-solutions&p=866"},"modified":"2025-06-03T08:14:03","modified_gmt":"2025-06-03T08:14:03","slug":"inflammatory-bowel-disease","status":"publish","type":"biomarker-solution","link":"https:\/\/www.nordicbioscience.com\/biomarker-solution\/inflammatory-bowel-disease\/inflammatory-bowel-disease\/","title":{"rendered":"Inflammatory Bowel Disease"},"content":{"rendered":"
\n \n
\n
\n
\n
\n

Biomarkers in inflammatory bowel disease (IBD)<\/h2>\n \n\n <\/div>\n
\n

Inflammatory bowel disease (IBD) is a chronic, relapsing, and remitting inflammatory disorder encompassing two main clinical entities: ulcerative colitis (UC)<\/a> and Crohn\u2018s disease (CD)<\/a>. The etiology of IBD involves a complex interplay between genetic susceptibility, environmental factors, and excessive immune response to the intestinal microbiota\u2014mediated by immune cells such as neutrophils, macrophages and T-cells.<\/p>\n

A hallmark of IBD is dysregulated proteolytic activity that throws off the balance of extracellular matrix (ECM) remodeling<\/a>, particularly collagen turnover within the mucosa and submucosa. This disruption in ECM remodeling contributes to key pathological features, including epithelial barrier dysfunction, chronic inflammation, and fibrosis.<\/p>\n

Generally, disrupted organ function in IBD is quantified through low patient compliance fecal calprotectin measurements. However, because of increased collagen turnover, ECM-based biomarkers allow researchers to measure calprotectin<\/a>, inflammation, epithelial damage and fibrosis directly in the blood, improving patient compliance and data availability.<\/p>\n <\/div>\n

\n

Our biomarker solutions in Crohn's disease, ulcerative colitis and intestinal fibrosis<\/h3>\n